RM Primary Logo - Humble.png
Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma
October 25, 2024 04:15 ET | Revolution Medicines, Inc.
First clinical results for RMC-9805, a RAS(ON) G12D-selective inhibitor, demonstrate encouraging tolerability and antitumor activity in patients with PDAC Investor webcast to be held Friday, October...
RM Primary Logo - Humble.png
Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma
October 23, 2024 06:00 ET | Revolution Medicines, Inc.
Encouraging progression-free survival and overall survival profile Safety findings consistent with previously reported data, no new safety signals observed Investor webcast to be held Friday,...
RM Primary Logo - Humble.png
Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast
October 07, 2024 09:00 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
metaswitch-logo-color-1000px.png
ENA Selects Metaswitch to Enhance Its IP Multimedia Communications
April 23, 2015 04:00 ET | Metaswitch Networks
LONDON, UNITED KINGDOM and NASHVILLE, TN--(Marketwired - April 23, 2015) - Metaswitch Networks, the world's leading network software provider, announced today that Education Networks of America (ENA),...